DPP-IV gluten digestive enzymes,
does it really help with Prevention of accidental gluten exposure and intestinal mucosal injury in celiac disease?
research showsThe claim that retail DPP-IV gluten digestive enzymes prevent accidental exposure or mucosal injury in celiac disease receives F with 10 points. Laboratory testing found that commercial supplements did not neutralize immunogenic gluten epitopes, and the AN-PEP study in celiac disease was a two-week exploratory trial with only 14 participants in the efficacy phase. Findings from some high-dose pharmaceutical glutenases cannot be transferred to retail DPP-IV blends, while current ACG guidance requires a strict gluten-free diet and lifelong follow-up. False reassurance leading to greater gluten exposure is a separate safety concern.
ads claimMarketing converts in-vitro digestion percentages or digestive support into removal of celiac-toxic epitopes and protection of intestinal mucosa. Relief of nonspecific digestive discomfort and protection from autoimmune celiac injury are different claims.
Useful facts when choosing a product
- DPP-IV cleaves proteins, but enzyme identity, activity, and acid stability vary across retail blends and cannot be assumed equivalent to a clinical-trial product.
- AN-PEP is a prolyl endoprotease rather than DPP-IV, and data from a specific enzyme under controlled conditions do not validate every gluten-digest supplement.
- Standard celiac management remains a strict gluten-free diet, nutritional assessment, and medical follow-up; digestive enzymes do not replace it.
- Intentional gluten consumption or relaxed cross-contamination control based on a supplement can permit small-intestinal injury even without immediate symptoms.
What the research actually shows
Janssen and colleagues assessed five retail supplements with mass spectrometry, R5 ELISA, and T-cell assays and found failure to neutralize immunogenic 26-mer and 33-mer peptides. Tack and colleagues gave recovered celiac patients about 7 g of gluten daily with AN-PEP or placebo for two weeks, but only 14 entered the efficacy analysis, precluding efficacy conclusions. A 494-participant phase 2 trial of latiglutenase, a combination of EP-B2 and SC-PEP, found no improvement in villous atrophy or symptoms. Failure of this more potent investigational enzyme does not support celiac protection by retail DPP-IV products, and the 2023 ACG guideline retains a strict gluten-free diet as current treatment.
Why this is classified as F (10)
Commercial DPP-IV products failed to degrade immunogenic epitopes, while the celiac AN-PEP trial was too small and short to demonstrate protection. Because guidelines do not accept enzymes as a replacement for a gluten-free diet and false reassurance can cause harm, the grade is F with 10 points.
Counterpoint. Pharmaceutical enzyme development continues, but different dose, formulation, and quality do not establish efficacy for retail supplements.
Rejudgment record. New verdict — Applied F to the mucosal-protection claim based on failure of retail DPP-IV blends to neutralize immunogenic epitopes, the tiny and short AN-PEP celiac pilot, and guidance retaining a strict gluten-free diet as current treatment
Sub-claim grades by effect
This ingredient is marketed for several effects. A single overall grade blends strong and weak claims together, so each effect is graded separately here. The overall grade reflects the strongest disconfirming or core claim.
| Effect (sub-claim) | Grade | Basis |
|---|---|---|
| Prevention of accidental celiac gluten exposure by retail DPP-IV blends | F | Neither toxic-epitope neutralization nor clinical protection has been demonstrated. |
| Prevention of small-intestinal mucosal injury in celiac disease | F | The AN-PEP pilot was too small, and a larger investigational-enzyme trial was negative. |
| Digestion of small amounts of gluten under some conditions | C | Specific AN-PEP preparations degrade gluten in vitro or in the stomach, but this is only a surrogate for mucosal protection. |
| Replacement for a gluten-free diet | F | Current guidance and clinical evidence clearly do not support replacement. |
Cross-check — Codex and Claude
Evidence Table
| Study | Design | Sample | Funding | Endpoint | Result | Weight |
|---|---|---|---|---|---|---|
| Janssen G et al. 2015 | In-vitro and immunologic comparison of retail supplements | 5 | DSM employees were coauthors with industry interests related to AN-PEP | R5 ELISA, mass spectrometry, and gluten-specific T-cell activation | Retail products failed to neutralize immunogenic gluten epitopes, while AN-PEP degraded them under test conditions. | Key direct refutation for retail products |
| Tack GJ et al. 2013 | Randomized double-blind placebo-controlled pilot trial | 14 | DSM Food Specialties supplied the AN-PEP preparation and randomization support | Symptoms, serology, and duodenal immunohistology after a two-week gluten challenge | No major safety signal emerged, but the sample and duration were too small to establish mucosal protection. | Direct exploratory human evidence for AN-PEP |
| Murray JA et al. 2017 | Multicenter randomized double-blind placebo-controlled phase 2 trial | 494 | Sponsored by Alvine Pharmaceuticals | Duodenal villous morphology and symptoms | The investigational EP-B2 and SC-PEP combination latiglutenase did not improve histology or symptoms versus placebo. | Large negative context for enzyme-protection claims |
Receipt — 4 References
All 4 cited sources were verified for existence at the original page (as of 2026-07-20).
Reviewed and approved: Chamgap Editorial Team · Approval date: 2026-07-20 · Corrections: none
Cite this verdict
[Chamgap] DPP-IV gluten digestive enzymes x mucosal protection in celiac disease — Evidence Grade F·10. 4 cited sources checked. Source: https://chamgap.com/en/verdicts/gut/dpp-iv-gluten-digestive-enzyme-celiac-mucosal-protection/ · CC BY 4.0CC BY 4.0 — free to use with attribution; do not distort grades, numbers, or verdict meaning.
What this document does and does not do
Chamgap is an information source. It reports what research has and has not confirmed; it does not tell readers what to take or buy. That decision belongs to readers and, when needed, medical or legal professionals. This verdict reflects literature available up to the search date and may change as new research appears. Nothing here is medical advice.